glp-1 agonist Classification of currently available glucagon-like peptide-1 receptor GLP-1 Receptor Agonists as Treatments
Description
Accessed 2025 Apr 25
doi: 10.1007/BF00220741
The FDA also recommends examining hard clinical endpoints such hepatic decompensations, transplant free survival, and all-cause mortality, although these results are not necessarily needed prior to drug approval given the long length of follow up potentially required
Exploratory analyses highlighted a link between treatment with tirzepatide and amelioration of biomarkers associated with inflammation and atherosclerotic cardiovascular diseases [84]
For example, a smaller amuse-bouche, a 5 oz
Novo Nordisks regulatory exclusivity for semaglutide ended on Jan
